Designer GLP1 poly-agonist peptides in the management of diabesity

Laura Statham, Melina Pelling, Petra Hanson, Ioannis Kyrou, Harpal Randeva, Thomas M Barber

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)
38 Downloads (Pure)


Introduction: To date, the 21 st Century has witnessed key developments in the management of diabesity (a conflation of obesity and Type 2 Diabetes Mellitus [T2D]), including Glucagon Like Peptide 1 (GLP1) receptor agonist therapies, and recently the ‘designer’ GLP1 Poly-agonist Peptides (GLP1PPs). Areas covered: A PubMed search of published data on the GLP1PP class of therapies was conducted. The gut-brain axis forms complex multi-directional interlinks that include autonomic nervous signaling, components of the gut microbiota (including metabolic by-products and gram-negative cell wall components [e.g. endotoxinaemia]), and incretin hormones that are secreted from the gut in response to the ingestion of nutrients. The development of dual-incretin agonist therapies includes combinations of the GLP1 peptide with Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon (Gcg), Cholecystokinin (CCK), Peptide YY (PYY), and Glucagon-Like Peptide 2 (GLP2). Triple incretin agonist therapies are also under development. Expert opinion: At the dawn of a new era in the therapeutic management of diabesity, the designer GLP1PP class holds great promise, with each novel combination building on a preexisting palimpsest of clinical data and insights. Future innovations of the GLP1PP class will likely enable medically induced weight loss and glycemic control in diabesity to rival or even out-perform those resulting from bariatric surgery.

Original languageEnglish
Pages (from-to)231-240
Number of pages10
JournalExpert review of endocrinology & metabolism
Issue number3
Publication statusPublished - 24 Apr 2023

Bibliographical note

© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (, which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent


  • Diabesity
  • Glucagon Like Peptide 1
  • Incretin
  • diabetes
  • obesity

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Designer GLP1 poly-agonist peptides in the management of diabesity'. Together they form a unique fingerprint.

Cite this